Characterization of Methylation Patterns in Cancer and Non-Cancer cfDNA

Overview

Nucleix EpiCheck® tests analyzes the methylation pattern in a panel of DNA methylation biomarkers and determines whether this pattern is consistent with cancer under test or with non-cancer tissue. This study is being performed as part of the development process of the Pan Cancer EpiCheck test which includes the identification of different methylation profiles in various cancer types and healthy controls.

Full Title of Study: “Characterization of Methylation Patterns in Cancer and Non-Cancer cfDNA, An Observational Multicenter Study”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: January 30, 2021

Detailed Description

The aim of this study is to characterize methylation patterns that will distinguish cancer from normal samples and will be able to recognize the origin of the cancer by collecting cfDNA (circulating free DNA) from blood samples collected from patients with a new diagnosis of cancer and from healthy volunteers who do not have diagnosis or history of cancer. Identifying those methylation patterns may assist in the development of blood test that will be able to detect the presence and the origin of wide range of human cancers

Interventions

  • Procedure: Blood collection
    • Peripheral blood collection via routine venipuncture

Arms, Groups and Cohorts

  • Cases Group
    • Peripheral blood collection via routine venipuncture
  • Control Group
    • Peripheral blood collection via routine venipuncture

Clinical Trial Outcome Measures

Primary Measures

  • To collect blood and urine samples and clinical data in order to characterize methylation patterns that will discriminate cancer and normal (non-cancer) samples and the origin of cancer
    • Time Frame: 72 Months
    • To collect blood and urine samples and clinical data in order to characterize methylation patterns that will discriminate cancer and normal (non-cancer) samples and the origin of cancer
  • To develop a molecular blood test that will be able to detect wide range of human cancers based on change in methylation patterns between cancer and normal samples
    • Time Frame: 72 Months
    • To develop a molecular blood test that will be able to detect wide range of human cancers based on change in methylation patterns between cancer and normal samples

Participating in This Clinical Trial

Inclusion Criteria – Cases: 1. Age ≥ 22 years 2. Subjects who are willing and able to provide written informed consent. 3. Subjects with confirmed diagnosis of cancer (primary or recurrent) at all stages, however did not yet undergo any surgery, chemotherapy, radiation or any other treatment for this cancerous lesion (including, but not limited to systemic therapies). Recent cancer staging should be within 60 days prior to baseline visit. Exclusion Criteria – Cases: 1. Known prior diagnosis of cancer except of: 1. Fully resected non-melanoma skin cancer 2. History of the original cancer in cases of recurrent disease. 2. Current co-diagnosis of another type of cancer. 3. Currently receiving, or ever received, any of the following therapies to treat their current cancer: surgical management of the cancer beyond that required to establish the cancer diagnosis; local, regional or systemic chemotherapy including chemoembolization; targeted therapy, immunotherapy including cancer vaccines; hormone therapy; or radiation therapy 4. Pregnancy (by self-report) 5. Current febrile illness 6. Acute exacerbation or flare of an inflammatory condition requiring escalation in medical therapy within 14 days prior to blood draw. 7. Recipient of organ transplant or prior non-autologous (allogeneic) bone marrow or stem cell transplant Inclusion Criteria – Controls: 1. Age 45 to 80 years 2. Subjects who are willing and able to provide written informed consent Exclusion Criteria – Controls: 1. Known current or prior diagnosis of cancer except of fully resected non-melanoma skin cancer 2. Currently in work-up due to suspicion of cancer of any kind 3. Oral or IV corticosteroid use in past 14 days prior to blood draw 4. Pregnancy (by self-report) 5. Current febrile illness 6. Acute exacerbation or flare of an inflammatory condition requiring escalation in medical therapy within 14 days prior to blood draw. 7. Recipient of organ transplant or prior non-autologous (allogeneic) bone marrow or stem cell transplant 8. Life expectancy < 24 months

Gender Eligibility: All

Minimum Age: 22 Years

Maximum Age: 80 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Nucleix Ltd.
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Shmulik Adler, Study Director, Nucleix Ltd.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.